Guardrails for Vaccine Innovation Are Under Threat

Key Takeaways:
A new FDA memo challenges long-standing vaccine-regulation practices by rejecting immunobridging, a method essential for rapid updates to influenza, COVID-19, pneumococcal, and HPV vaccines.
Twelve former FDA commissioners warn that requiring full randomized trials for routine vaccine updates would slow innovation, delay protection against evolving pathogens, and disrupt the U.S. vaccine-development ecosystem.
The memo relies on unverified VAERS reports to assert vaccine-related deaths while simultaneously discouraging scientific transparency and limiting internal debate—raising concerns about regulatory integrity and public trust.
Shifting vaccine policies across federal agencies could weaken evidence-based immunization standards and reduce national preparedness for seasonal and emerging infectious-disease threats.

A Historic Warning from Former FDA Commissioners

In an extraordinary moment for U.S. public health governance, twelve former U.S. Food and Drug Administration (FDA) commissioners and acting commissioners published a joint Perspective article in The New England Journal of Medicine (NEJM) warning that recent internal policy moves at the agency threaten the scientific foundation of vaccine regulation.¹ The authors — leaders who collectively guided the FDA for more than three decades — describe the current situation as a break from long-established norms designed to ensure that vaccines remain safe, effective, and available when they are needed most.

Their warning comes during a period of marked internal turbulence at the FDA, including the release of a memo from the director of the Center for Biologics Evaluation and Research (CBER) outlining sweeping changes to vaccine oversight and suggesting that COVID-19 vaccines “probably contributed” to the deaths of at least 10 children—an assertion based solely on passive reports from the Vaccine Adverse Event Reporting System (VAERS).^2,3 The memo has already prompted concerns from regulators, former officials, and public-health experts about its scientific rigor, its interpretation of safety data, and its potential to reshape vaccine approval standards in ways that diverge sharply from decades of evidence-based practice.^1,3,4

The stakes extend far beyond the internal dynamics of the agency. Biopharma developers depend on consistent, predictable regulatory pathways, particularly for vaccines that must be updated frequently to match evolving pathogens. Abrupt shifts in scientific standards, coupled with signals of diminished transparency and advisory-committee engagement, risk disrupting innovation and sowing uncertainty among companies that play a central role in maintaining national and global public health preparedness.

As the former commissioners caution, the direction the FDA takes now will help determine whether the United States continues to lead in vaccine science or whether regulatory instability will erode public trust and compromise the ability to respond swiftly to infectious-disease threats.

What the Prasad Memo Asserted

The internal memo at the center of this controversy makes several sweeping claims that depart sharply from established vaccine-regulatory practice. Most prominently, it asserts that COVID-19 vaccines “probably contributed” to the deaths of at least 10 children, a conclusion drawn entirely from unverified submissions to VAERS rather than from controlled epidemiologic analysis.

The memo goes further, characterizing communication of scientific concerns to external stakeholders as “unethical” or “illegal,” according to the summary provided by the former FDA commissioners in NEJM.¹ It also tells staff who disagree with the new framework to “submit your resignation letters,” language cited directly by the former commissioners as evidence of an effort to stifle internal dissent. In addition, the memo directs that scientific debates be kept within the agency until leadership deems them ready for release, a posture that the former commissioners argue undermines norms of transparency that have historically strengthened public trust.

Together, these assertions reflect a consolidation of decision-making authority and a significant narrowing of acceptable scientific discourse within the agency — moves that alarmed regulators and public-health experts across the political spectrum.^1,3

Beyond its rhetorical posture, the memo lays out a regulatory framework that would dramatically restructure how vaccines are evaluated and updated. Central to this shift is the rejection of immunobridging, a long-standing and evidence-supported approach that uses immune-response markers as surrogates for clinical efficacy in vaccines with well-established mechanisms of action.¹ Eliminating immunobridging would make it far more difficult to update vaccines for rapidly evolving pathogens, an area where timely reformulation is essential.

Instead, the memo proposes that updated or reformulated vaccines undergo new randomized clinical trials, even when the underlying platform and safety profile are already well characterized. According to reporting and the NEJM commentary, this requirement would apply not just to COVID-19 vaccines but potentially to seasonal influenza vaccines, which are updated annually based on immunologic correlates, as well as to products administered in combination schedules or during pregnancy.

The former commissioners argue that these proposed policy shifts represent not incremental adjustments but a fundamental redefinition of the FDA’s role, one that would impose substantial scientific, operational, and financial burdens on vaccine developers while reducing the flexibility needed to respond to emerging infectious threats.

The Former Commissioners’ Critique

Scientific and Regulatory Substance

In their Perspective piece, the former commissioners warn that the proposed regulatory overhaul would dismantle the scientific foundation that enables timely, evidence-based vaccine updates.1 Central to their critique is the memo’s rejection of immunobridging, which. underlies the routine updating of seasonal influenza vaccines, supports the expansion of pneumococcal conjugate vaccines to additional serotypes, and has been fundamental in evaluating COVID-19 vaccine reformulations and in authorizing vaccines such as HPV where immune correlates reliably predict protection.1,5

By contrast, the new framework would require fresh randomized clinical trials (RCTs) for many updated or reformulated products, even when platforms and safety profiles are well characterized.1,4 The former commissioners argue that demanding full-scale RCTs for every strain update or incremental modification is scientifically unnecessary and operationally unworkable, given how quickly pathogens such as influenza and SARS-CoV-2 evolve.

They further emphasize that this new regulatory bar would disproportionately burden smaller vaccine developers, who often lack the resources for repeated large trials, thereby reducing competition and slowing the introduction of improved vaccines.

Governance and Process Issues

Beyond the scientific concerns, the former commissioners highlight a series of process violations that they view as incompatible with the FDA’s statutory responsibilities. They argue that adopting changes of this magnitude without public guidance, advisory-committee discussion, or opportunity for comment conflicts directly with the Administrative Procedure Act and the FDA’s Good Guidance Practices, which require transparency and external input for major policy shifts.¹

They also point to broader signals that agency leadership intends to sideline or reduce the use of advisory committees, including the Vaccines and Related Biological Products Advisory Committee (VRBPAC), which has historically ensured that controversial decisions receive independent, public scientific review.

Equally concerning, in their view, are the memo’s directives discouraging staff from expressing scientific disagreements and instructing them to keep debates internal or resign — actions the former commissioners describe as antithetical to the open scientific discourse necessary for sound regulatory decision-making.

Public Health Consequences

The former commissioners warn that the proposed framework would have serious downstream effects on public health. Eliminating immunobridging and requiring full trials for routine updates would delay the release of vaccines that must be matched to rapidly changing pathogens, including influenza and SARS-CoV-2. Such delays, they argue, would reduce the effectiveness of vaccination programs and leave populations more exposed during seasonal and emergent waves of infection.

They also note that the heightened clinical-trial burden could limit availability and affordability, creating barriers for older adults, immunocompromised people, and others at high risk who depend on timely access to well-matched vaccines.

In the aggregate, these changes would increase national vulnerability to vaccine-preventable diseases, weaken pandemic preparedness, and undermine public trust in the regulatory system.

VAERS, Causality, and Misinterpretation

A central concern raised by the former commissioners is the memo’s heavy reliance on VAERS to support the assertion that COVID-19 vaccines “probably contributed” to the deaths of at least ten children. VAERS is explicitly designed as a passive surveillance system, meaning it accepts reports from any source without verification, and its data are subject to significant reporting biases and the absence of control groups.^6,7 These characteristics make VAERS a valuable signal-detection tool, but they also mean its raw reports cannot establish that a vaccine caused a particular adverse event, a principle repeatedly emphasized in CDC guidance and the scientific literature.

Despite these limitations, the memo treats VAERS submissions as the basis for determining that multiple pediatric deaths were likely attributable to vaccination, an interpretation that substitutes unverified reports for the formal epidemiologic analyses normally required to assess causality.^2,3 According to news reports, the cases cited in the memo involve children aged 7–16 whose deaths were reported to VAERS between 2021 and 2024, but the memo does not present evidence beyond the initial reports themselves or describe any independent adjudication.

The former commissioners argue that this approach reflects a fundamental misunderstanding of how vaccine-safety data must be evaluated. In their critique, they note that VAERS reports are hypothesis-generating, not confirmatory, and that causality assessments require rigorously designed studies, medical record review, and multi-source surveillance systems that are not referenced in the memo.¹ By relying on unverified VAERS entries to justify sweeping policy changes, they contend, the memo lacks methodological rigor and risks misleading both policymakers and the public about vaccine safety.

Adjacent Policy Turmoil

Although the former commissioners focus on FDA-specific actions, their warning comes amid a broader landscape of vaccine-policy instability across federal agencies, particularly at the CDC and its Advisory Committee on Immunization Practices (ACIP). Together, these dynamics amplify concerns that long-standing scientific norms guiding U.S. immunization policy are at risk.

Recent reporting has documented significant changes in the composition and orientation of federal vaccine advisory bodies. Several sources describe newly appointed advisers aligned with RFK Jr.’s vaccine-skeptic positions, raising the possibility that ACIP deliberations will shift away from long-established, evidence-driven practices. In particular, experts have expressed concern that the December ACIP meeting is structured in a way that may “sow distrust and spread fear,” according to pediatric infectious-disease specialists cited by KFF Health News.⁸

One of the most consequential signs of this turbulence is ACIP’s pending vote on whether to delay the first dose of the hepatitis B vaccine from birth to two months. Reuters reports that the proposal would overturn more than three decades of CDC guidance recommending administration within 24 hours of birth to prevent perinatal transmission, a strategy associated with dramatic reductions in childhood hepatitis B infections.9 Independent experts cited by Reuters that altering the birth-dose schedule could undermine a proven public-health intervention and increase the risk of preventable infections in newborns and young children.

These developments — combined with the FDA memo’s proposals to reject immunobridging, curtail advisory-committee involvement, and elevate unverified safety signals — reflect a broader federal pressure on evidence-based vaccine norms. Reporting notes that the administration has questioned vaccine safety and necessity for months, and that ACIP has postponed or reconsidered votes on multiple elements of the childhood immunization schedule, including hepatitis B.¹⁰

Viewed together, these shifts signal a potential realignment of U.S. vaccine policy toward approaches that deprioritize established scientific frameworks, heightening concern among public-health experts about erosion of the systems that support vaccine uptake, rapid pathogen response, and protection of vulnerable populations.^9,11

Our Perspective

The issues raised by the former FDA commissioners underscore what is at stake for both public health and the life sciences sector.. As documented in multiple peer-reviewed sources, immunobridging enables timely updates of influenza vaccines, supports expansion of pneumococcal conjugate vaccines, and has proven essential for COVID-19 and HPV vaccine programs.⁵ Abandoning this framework would dismantle one of the most important tools for keeping pace with rapidly evolving pathogens.

Equally critical is the need for a predictable, evidence-based regulatory framework that allows vaccine developers to plan and execute development programs with confidence. The biopharmaceutical ecosystem depends on stability, particularly in areas where products require frequent updating, specialized manufacturing capacity, and complex supply chains. When scientific standards change abruptly or are replaced by rigid requirements untethered from decades of empirical evidence, it creates uncertainty that reverberates across the entire development landscape. Smaller innovators, who often drive early-stage vaccine breakthroughs, are especially vulnerable to these shifts.

The memo’s framing also highlights the risks of politicized decision-making and the suppression of scientific discourse. As the former commissioners emphasize, the FDA’s strength has always rested on transparent debate, pluralistic expertise, and an institutional culture that encourages scientists to raise concerns openly. Directives that label external scientific communication as “unethical,” instruct dissenting staff to resign, or restrict internal debate compromise the agency’s credibility and undermine the public’s trust in its decisions.

Finally, global vaccine preparedness depends on regulatory pathways that remain flexible, timely, and scientifically grounded. The world’s ability to respond to seasonal influenza, new variants of SARS-CoV-2, and emerging pathogens hinges on the rapid assessment and deployment of updated vaccines. Replacing established surrogate-endpoint frameworks with repeated randomized trials — even for minor antigenic updates — would slow the cycle of reformulation and leave populations more exposed at moments when speed is essential. In a global environment where infectious threats emerge unpredictably, the United States cannot afford to weaken the very processes that have enabled it to lead vaccine innovation for decades.

Conclusion

The concerns outlined by 12 former FDA commissioners mark an inflection point for U.S. vaccine regulation. At stake are not only the scientific standards that underpin vaccine development, but also the integrity and stability of the regulatory framework that biopharmaceutical innovators depend on. A system built over decades that balances speed and rigor, encourages open scientific debate, and adapts to evolving pathogens cannot be sustained if foundational practices like immunobridging are discarded without evidence or due process.

For industry and public health alike, predictable, science-driven regulation is not a luxury — it is a prerequisite. Vaccines must be updated quickly and reliably to meet shifting epidemiologic realities, and developers must be able to invest confidently in platforms that depend on flexible yet rigorous evaluation pathways. When regulatory decisions are shaped by misinterpretation of surveillance data, suppression of internal discourse, or the erosion of advisory-committee oversight, the consequences extend far beyond a single memo or policy shift.

Ultimately, the ability of the United States to maintain its global leadership in vaccine innovation and to protect its population from preventable disease rests on a commitment to transparent deliberation, robust scientific standards, and respect for the evidence-based processes that have long guided FDA decision-making. The former commissioners’ warning is therefore not simply a critique of one internal document; it is a call to preserve the principles that enable vaccines to remain among the most effective tools in modern medicine.